MURA

Mural Oncology plc is Ireland-based clinical-stage oncology company. The Company is a biotechnology company focused on using its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer with the goal of delivering meaningful and clinical benefits to people living with cancer. The Company is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. The lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational-engineered cytokine fusion protein that selectively binds to the intermediate-affinity interleukin-2 (IL-2) receptor. The Company has also developed engineered therapies targeting the interleukin-18 (IL-18) and interleukin-12 (IL-12) pathways, which have demonstrated therapeutic potential in third-party preclinical and clinical studies.

Wall Street analysts forecast MURA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MURA is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Mural Oncology PLC revenue for the last quarter amounts to -3.97M USD, decreased -88.37 % YoY.

Mural Oncology PLC. EPS for the last quarter amounts to -18481000.00 USD, decreased -38.59 % YoY.

Mural Oncology PLC (MURA) has 116 emplpoyees as of December 15 2025.

Today MURA has the market capitalization of 0.00 USD.